title: The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013.
abstract: This systematic literature review was conducted to summarize the direct and indirect costs per patient that are associated with uterine fibroid tumors in international studies. A search with predefined search terms was conducted in MEDLINE and EMBASE for studies that were published from January 2000 to November 2013. The review included primary studies that were in English and that reported either direct costs (drug costs, procedure costs, and medical service costs) or indirect costs (such as productivity loss) among patients with uterine fibroid tumors. A total of 26 studies that were identified and included in the data extraction included 19 studies in the United States, 2 studies in the Netherlands, 1 study each in Germany, China, Italy, and Canada, and 1 study reported data that were collected from 3 countries: Germany, France, and England. The studies differed substantially in perspectives that were adopted for analysis, research designs, data elements that were collected, setting, populations, and outcome measurements. Among 3 studies that reported total direct costs during the year after uterine fibroid tumor diagnosis, 2 studies reported an average of $9473 and $9319 per patient, respectively; 2 studies reported the excess costs over controls to be $6076 and $5427, respectively. The indirect costs per patient ranged from $2399-15,549, and the excess indirect cost per patient over control groups ranged from $323-4824 in the year after the diagnosis. The total costs, sum of direct and indirect costs, ranged from $11,717-25,023 per patient per year, after diagnosis or surgery among patients with uterine fibroid tumors. Compared with control subjects, the additional annual cost ranged from $2200-15,952 per patient. The results of this systematic literature review highlight the substantial direct and indirect costs that are associated with uterine fibroid tumors to health care payers and society. The large number and the variety of studies identified also emphasize the growing awareness of the significant economic impact of uterine fibroid tumors. Current gaps that were identified through this review warrant further investigation to elucidate fully the economic burden of uterine fibroid tumors, including, but not limited to, burden from the patient's perspective and the entirety of indirect costs.
authors.affiliation: AbbVie, Inc, North Chicago, IL. Electronic address: ahmed.m.soliman@abbvie.com.
authors.forename: Ahmed M
authors.initials: AM
authors.lastname: Soliman
authors.affiliation: Analysis Group, Inc, Boston, MA.
authors.forename: Hongbo
authors.initials: H
authors.lastname: Yang
authors.affiliation: Analysis Group, Inc, Boston, MA.
authors.forename: Ella Xiaoyan
authors.initials: EX
authors.lastname: Du
authors.affiliation: Analysis Group, Inc, New York, NY.
authors.forename: Sneha S
authors.initials: SS
authors.lastname: Kelkar
authors.affiliation: Department of Obstetrics and Gynecology, Georgetown University School of Medicine, Washington, DC.
authors.forename: Craig
authors.initials: C
authors.lastname: Winkel
mesh_terms: D003277:Contraceptives, Oral, Combined / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D016527:Drug Costs; D004526:Efficiency; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000037:antagonists & inhibitors; D017048:Health Care Costs; D006801:Humans; D007044:Hysterectomy / Q000191:economics; D007889:Leiomyoma / Q000191:economics* / Q000628:therapy; D011372:Progestins / Q000191:economics / Q000627:therapeutic use; D063186:Uterine Myomectomy / Q000191:economics; D014594:Uterine Neoplasms / Q000191:economics* / Q000628:therapy
chemical_list: D003277:Contraceptives, Oral, Combined; D011372:Progestins; D007987:Gonadotropin-Releasing Hormone
keywords: direct cost; indirect cost; systematic literature review; uterine fibroid tumor